Literature DB >> 34021445

Overexpression of miRNA-9 enhances galectin-3 levels in oral cavity cancers.

Yunxia Wan1,2, Xi Zhang1,2, Kai Dun Tang1,2, Tony Blick1,2, Liz Kenny3,4, Erik W Thompson1,2, Chamindie Punyadeera5,6.   

Abstract

Oral cavity cancer (OCC) is the predominant subtype of head and neck cancer (HNC) and has up to 50% mortality. Genome-wide microRNA (miR) sequencing data indicates overexpression of miR-9-5p in HNC tumours, however, the biological role of miR-9-5p in OCC is complex; it can either act as a tumour suppressor or an oncomir, regulating many target genes at the post-transcriptional level. We have investigated the overexpression of miR-9-5p in three OCC cell lines. We have evaluated its expression levels and Galectin-3 as potential biomarkers in saliva samples collected from controls and OCC patients. We found that over expression of miR-9-5p in OCC cell lines resulted in a significant reduction in cell proliferation and migration, and an increase in apoptosis, which was paralleled by an increase in Galectin-3 secretion and export of Galectin-3 protein. Our data are consistent with miR-9-5p being a modulator of Galectin-3 via the AKT/γ-catenin pathway. In addition, the positive correlation between the levels of miR-9-5p expression and secreted Galectin-3 in saliva reflects a similar relationship in vivo, and supports the utility of their integrative evaluation in OCC. Our findings indicate that both miR-9-5p and Galectin-3 are critical biomolecules in the progression of OCC.

Entities:  

Keywords:  AKT; Galectin-3; MMP; Oral cavity cancer; miR-9-5p; γ-catenin

Mesh:

Substances:

Year:  2021        PMID: 34021445     DOI: 10.1007/s11033-021-06398-7

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  52 in total

1.  Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas.

Authors:  Jacob Minor; Xiaotian Wang; Fang Zhang; John Song; Antonio Jimeno; Xiao-Jing Wang; Xian Lu; Neil Gross; Molly Kulesz-Martin; Daren Wang; Shi-Long Lu
Journal:  Oral Oncol       Date:  2011-11-30       Impact factor: 5.337

Review 2.  Head and neck squamous cell carcinoma in young patients.

Authors:  Hester S van Monsjou; Volkert B Wreesmann; Michiel W M van den Brekel; Alfons J M Balm
Journal:  Oral Oncol       Date:  2013-10-06       Impact factor: 5.337

Review 3.  miRNAs in human papilloma virus associated oral and oropharyngeal squamous cell carcinomas.

Authors:  Carolina Salazar; Diego Calvopiña; Chamindie Punyadeera
Journal:  Expert Rev Mol Diagn       Date:  2014-09-15       Impact factor: 5.225

4.  Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers.

Authors:  Anil K Chaturvedi; William F Anderson; Joannie Lortet-Tieulent; Maria Paula Curado; Jacques Ferlay; Silvia Franceschi; Philip S Rosenberg; Freddie Bray; Maura L Gillison
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544

Review 5.  Clinicopathological prognostic implicators of oral squamous cell carcinoma: need to understand and revise.

Authors:  Kiran B Jadhav; Nidhi Gupta
Journal:  N Am J Med Sci       Date:  2013-12

6.  Genome-wide miRNA profiling reinforces the importance of miR-9 in human papillomavirus associated oral and oropharyngeal head and neck cancer.

Authors:  Ksenija Božinović; Ivan Sabol; Emil Dediol; Nina Milutin Gašperov; Spomenka Manojlović; Zuzana Vojtechova; Ruth Tachezy; Magdalena Grce
Journal:  Sci Rep       Date:  2019-02-19       Impact factor: 4.379

7.  Evaluation and Prognostic Significance of Galectin-3 Expression in Oral Squamous Cell Carcinoma.

Authors:  Serdar Tokmak; Deniz Arık; Özgür Pınarbaşlı; Melek Kezban Gürbüz; Mustafa Fuat Açıkalın
Journal:  Ear Nose Throat J       Date:  2019-12-15       Impact factor: 1.697

8.  Salivary miRNA panel to detect HPV-positive and HPV-negative head and neck cancer patients.

Authors:  Yunxia Wan; Dimitrios Vagenas; Carolina Salazar; Liz Kenny; Chris Perry; Diego Calvopiña; Chamindie Punyadeera
Journal:  Oncotarget       Date:  2017-10-10

Review 9.  The versatile nature of miR-9/9* in human cancer.

Authors:  Katarzyna Nowek; Erik A C Wiemer; Mojca Jongen-Lavrencic
Journal:  Oncotarget       Date:  2018-04-17

10.  Trends in clinical features and survival of oral cavity cancer: fifty years of experience with 3,362 consecutive cases from a single institution.

Authors:  Shu-Wei Chen; Quan Zhang; Zhu-Ming Guo; Wen-Kuan Chen; Wei-Wei Liu; Yan-Feng Chen; Qiu-Li Li; Xue-Kui Liu; Hao Li; Dian Ou-Yang; Wei-Chao Chen; Xiao-Yan Fu; Xi-Di Wang; An-Kui Yang; Jin-Xin Bei; Ming Song
Journal:  Cancer Manag Res       Date:  2018-10-12       Impact factor: 3.989

View more
  2 in total

1.  Application of circulating tumour cells to predict response to treatment in head and neck cancer.

Authors:  Xi Zhang; Chameera Ekanayake Weeramange; Brett G M Hughes; Sarju Vasani; Zhen Yu Liu; Majid Ebrahimi Warkiani; Gunter Hartel; Rahul Ladwa; Jean Paul Thiery; Liz Kenny; Chamindie Punyadeera
Journal:  Cell Oncol (Dordr)       Date:  2022-06-23       Impact factor: 7.051

Review 2.  Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.

Authors:  Arsinoe C Thomaidou; Panagiota Batsaki; Maria Adamaki; Maria Goulielmaki; Constantin N Baxevanis; Vassilis Zoumpourlis; Sotirios P Fortis
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.